History
Documents created during the development process.
Review proposal consultation
Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313) [ID819]: equality impact assessment form - guidance development
-
Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313) [ID819]: equality impact assessment form - guidance development
-
Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313) [ID819]: final appraisal determination
-
-
Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313) [ID819]: final appraisal determination document
-
-
Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313) [ID819]: committee papers information
-
Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313) [ID819]: committee papers (PDF 1.02 MB)
Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313): appraisal consultation
-
Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313): appraisal consultation
-
Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313): appraisal consultation document
-
-
Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313): committee papers information
-
Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313): committee papers (PDF 1.82 MB)